Alnylam Pharmaceuticals, Inc.
$310.49
▲
0.67%
2026-04-22 10:12:13
www.alnylam.com
NMS: ALNY
Explore Alnylam Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$41.46 B
Current Price
$310.49
52W High / Low
$495.55 / $228.28
Stock P/E
133.51
Book Value
$5.96
Dividend Yield
—
ROCE
14.33%
ROE
73.28%
Face Value
—
EPS
$2.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2,500
Beta
0.38
Debt / Equity
376.19
Current Ratio
2.76
Quick Ratio
2.71
Forward P/E
22.68
Price / Sales
11.57
Enterprise Value
$42.78 B
EV / EBITDA
76.77
EV / Revenue
11.52
Rating
Buy
Target Price
$449.32
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
Cons
- Leverage is relatively high.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 2. | Altimmune, Inc. | $3.56 | — | $463.05 M | — | -35.67% | -50.57% | $7.73 / $2.87 | $2.03 |
| 3. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 4. | Canton Strategic Holdings, Inc. | $3.51 | — | $194.33 M | — | -3.9% | -17.99% | $9.08 / $1.05 | $10.72 |
| 5. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 6. | PDS Biotechnology Corporation | $1.29 | — | $72 M | — | -150.13% | -2.44% | $1.92 / $0.51 | $-4.02 |
| 7. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.1 B | 1.25 B | 773.69 M | 594.19 M | 593.17 M | — |
| Operating Profit | 131.72 M | 367.98 M | -16.2 M | 18.08 M | -105.16 M | — |
| Net Profit | 186.42 M | 251.08 M | -66.28 M | -57.48 M | -83.76 M | — |
| EPS in Rs | 1.4 | 1.88 | -0.5 | -0.43 | -0.63 | -0.87 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.71 B | 2.25 B | 1.83 B | 1.04 B |
| Operating Profit | 501.58 M | -176.88 M | -282.18 M | -785.07 M |
| Net Profit | 313.75 M | -278.16 M | -440.24 M | -1.13 B |
| EPS in Rs | 2.35 | -2.08 | -3.3 | -8.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.97 B | 4.24 B | 3.83 B | 3.55 B |
| Total Liabilities | 4.18 B | 4.17 B | 4.05 B | 3.7 B |
| Equity | 789.18 M | 67.09 M | -220.64 M | -158.22 M |
| Current Assets | 4.05 B | 3.3 B | 2.98 B | 2.69 B |
| Current Liabilities | 1.47 B | 1.19 B | 967.79 M | 767.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 524.08 M | -8.31 M | 104.16 M | -541.27 M |
| Investing CF | 436.33 M | -116.84 M | -336.35 M | 169.35 M |
| Financing CF | -305.19 M | 294.16 M | 172.13 M | 425.75 M |
| Free CF | 465.38 M | -42.59 M | 41.95 M | -613.33 M |
| Capex | -58.7 M | -34.28 M | -62.21 M | -72.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 65.19% | 22.97% | 76.23% | — |
| Earnings Growth % | 212.79% | 36.82% | 61.08% | — |
| Profit Margin % | 8.45% | -12.37% | -24.08% | -109.04% |
| Operating Margin % | 13.51% | -7.87% | -15.43% | -75.68% |
| Gross Margin % | 81.64% | 85.62% | 83.02% | 83.73% |
| EBITDA Margin % | 17% | -7.95% | -14.12% | -89.31% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.